Cargando…
(18)F-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes
BACKGROUND: Muscle enzymes are the major noninvasive diagnostic parameters useful in polymyositis/dermatomyositis (PM/DM). Few studies have yet correlated findings on (18)F-FDG PET with disease activity in patients with PM/DM. PURPOSE: We evaluated (18)F-FDG muscle uptake in patients with PM/DM comp...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218055/ https://www.ncbi.nlm.nih.gov/pubmed/34191182 http://dx.doi.org/10.1186/s41824-020-00084-w |
_version_ | 1783710712269373440 |
---|---|
author | Arai-Okuda, Hanae Norikane, Takashi Yamamoto, Yuka Mitamura, Katsuya Fujimoto, Kengo Takami, Yasukage Wakiya, Risa Nakashima, Shusaku Dobashi, Hiroaki Nishiyama, Yoshihiro |
author_facet | Arai-Okuda, Hanae Norikane, Takashi Yamamoto, Yuka Mitamura, Katsuya Fujimoto, Kengo Takami, Yasukage Wakiya, Risa Nakashima, Shusaku Dobashi, Hiroaki Nishiyama, Yoshihiro |
author_sort | Arai-Okuda, Hanae |
collection | PubMed |
description | BACKGROUND: Muscle enzymes are the major noninvasive diagnostic parameters useful in polymyositis/dermatomyositis (PM/DM). Few studies have yet correlated findings on (18)F-FDG PET with disease activity in patients with PM/DM. PURPOSE: We evaluated (18)F-FDG muscle uptake in patients with PM/DM compared with non-muscular diseases and correlated the results with serum muscle enzymes. METHODS: A total of 28 patients with untreated PM/DM and 28 control patients with non-muscular diseases were examined with (18)F-FDG PET/CT. (18)F-FDG uptake was evaluated in 9 proximal skeletal muscle regions bilaterally. The uptake was scored as follows: 0 = less than that of the mediastinal blood vessels, 1 = greater than or equal to that of the mediastinal blood vessels, and 2 = greater than or equal to that of the liver. A score 1 or 2 was considered positive. The mean and maximum standardized uptake values (SUV) were calculated in each muscle and were averaged for all muscle regions. PET findings were correlated with serum muscle enzymes. RESULTS: (18)F-FDG uptake was observed in 82% of patients with PM/DM and 7% of control patients. The number of positive regions, total score, mean SUVmean, and mean SUVmax in patients with PM/DM were significantly higher than those in the control patients (all P < 0.001). The total score of 2 was the best cut-off value that could discriminate patients with PM/DM from control patients. The total score, mean SUVmean, and mean SUVmax showed significant correlations with creatine kinase (P = 0.047, 0.002, 0.010, respectively) and aldolase (P = 0.036, 0.005, 0.038, respectively). CONCLUSION: (18)F-FDG PET/CT using visual and SUV methods demonstrated its usefulness by discriminating PM/DM from non-muscular diseases and correlating with serum muscle enzymes in patients with PM/DM. |
format | Online Article Text |
id | pubmed-8218055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-82180552021-06-24 (18)F-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes Arai-Okuda, Hanae Norikane, Takashi Yamamoto, Yuka Mitamura, Katsuya Fujimoto, Kengo Takami, Yasukage Wakiya, Risa Nakashima, Shusaku Dobashi, Hiroaki Nishiyama, Yoshihiro Eur J Hybrid Imaging Original Article BACKGROUND: Muscle enzymes are the major noninvasive diagnostic parameters useful in polymyositis/dermatomyositis (PM/DM). Few studies have yet correlated findings on (18)F-FDG PET with disease activity in patients with PM/DM. PURPOSE: We evaluated (18)F-FDG muscle uptake in patients with PM/DM compared with non-muscular diseases and correlated the results with serum muscle enzymes. METHODS: A total of 28 patients with untreated PM/DM and 28 control patients with non-muscular diseases were examined with (18)F-FDG PET/CT. (18)F-FDG uptake was evaluated in 9 proximal skeletal muscle regions bilaterally. The uptake was scored as follows: 0 = less than that of the mediastinal blood vessels, 1 = greater than or equal to that of the mediastinal blood vessels, and 2 = greater than or equal to that of the liver. A score 1 or 2 was considered positive. The mean and maximum standardized uptake values (SUV) were calculated in each muscle and were averaged for all muscle regions. PET findings were correlated with serum muscle enzymes. RESULTS: (18)F-FDG uptake was observed in 82% of patients with PM/DM and 7% of control patients. The number of positive regions, total score, mean SUVmean, and mean SUVmax in patients with PM/DM were significantly higher than those in the control patients (all P < 0.001). The total score of 2 was the best cut-off value that could discriminate patients with PM/DM from control patients. The total score, mean SUVmean, and mean SUVmax showed significant correlations with creatine kinase (P = 0.047, 0.002, 0.010, respectively) and aldolase (P = 0.036, 0.005, 0.038, respectively). CONCLUSION: (18)F-FDG PET/CT using visual and SUV methods demonstrated its usefulness by discriminating PM/DM from non-muscular diseases and correlating with serum muscle enzymes in patients with PM/DM. Springer International Publishing 2020-08-12 /pmc/articles/PMC8218055/ /pubmed/34191182 http://dx.doi.org/10.1186/s41824-020-00084-w Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Arai-Okuda, Hanae Norikane, Takashi Yamamoto, Yuka Mitamura, Katsuya Fujimoto, Kengo Takami, Yasukage Wakiya, Risa Nakashima, Shusaku Dobashi, Hiroaki Nishiyama, Yoshihiro (18)F-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes |
title | (18)F-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes |
title_full | (18)F-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes |
title_fullStr | (18)F-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes |
title_full_unstemmed | (18)F-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes |
title_short | (18)F-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes |
title_sort | (18)f-fdg pet/ct in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218055/ https://www.ncbi.nlm.nih.gov/pubmed/34191182 http://dx.doi.org/10.1186/s41824-020-00084-w |
work_keys_str_mv | AT araiokudahanae 18ffdgpetctinpatientswithpolymyositisdermatomyositiscorrelationwithserummuscleenzymes AT norikanetakashi 18ffdgpetctinpatientswithpolymyositisdermatomyositiscorrelationwithserummuscleenzymes AT yamamotoyuka 18ffdgpetctinpatientswithpolymyositisdermatomyositiscorrelationwithserummuscleenzymes AT mitamurakatsuya 18ffdgpetctinpatientswithpolymyositisdermatomyositiscorrelationwithserummuscleenzymes AT fujimotokengo 18ffdgpetctinpatientswithpolymyositisdermatomyositiscorrelationwithserummuscleenzymes AT takamiyasukage 18ffdgpetctinpatientswithpolymyositisdermatomyositiscorrelationwithserummuscleenzymes AT wakiyarisa 18ffdgpetctinpatientswithpolymyositisdermatomyositiscorrelationwithserummuscleenzymes AT nakashimashusaku 18ffdgpetctinpatientswithpolymyositisdermatomyositiscorrelationwithserummuscleenzymes AT dobashihiroaki 18ffdgpetctinpatientswithpolymyositisdermatomyositiscorrelationwithserummuscleenzymes AT nishiyamayoshihiro 18ffdgpetctinpatientswithpolymyositisdermatomyositiscorrelationwithserummuscleenzymes |